CD123 by IHC
CD123 by IHC-12376 - Technical only, 12379 - Technical & interpretation
CD123 by IHC
12376 - Technical only, 12379 - Technical & interpretation
LAB12376
LAB12379
LAB12379
IL-3 alpha-chain receptor
- All IHC stains will include a positive control tissue
- CD123 identifies blastic plasmacytoid dendritic cell (BPDC) neoplasms, which tend to involve multiple sites, with predilection for skin (almost 100% of cases), followed by bone marrow (60-90%) and other sites. 10-20% of cases are associated with or develop into AML
- CD 123 is most useful in an antibody panel designed to detect BPDC neoplasms, which are CD4+, CD56+, CD68+ (50% have cytoplasmic dot staining), and TdT (33% positive). Tumors that share some but not all immunophenotypic features of BPDC are better classified as "acute leukemia of ambiguous lineage"
Tissue
Submit a formalin-fixed, paraffin embedded tissue block
Formalin-fixed, paraffin embedded (FFPE) tissue block
FFPE tissue section mounted on a charged, unstained slide
Ambient (preferred)
- Unlabeled/mislabeled block
- Insufficient tissue
- Slides broken beyond repair
AHL - Immunohistochemistry
Mo - Fr
1 - 2 days
Immunohistochemical staining and microscopic examination
If requested, an interpretive report will be provided
Specifications
- CD123 antibody reacts with IL-3 receptor alpha chain which is expressed on normal plasmacytoid dendritic cells
- CD 123 reactivity with does not occur on other hematopoietic progenitor cells, but has not been extensively studied
Staining pattern
- Membrane -based staining
References
- WHO (2008) classification of tumors of hematopoietic and lymphoid tissues, p145-147.
88342 - 1st stain
88341 - each additional stain
88341 - each additional stain
06/16/2017
10/17/2018
01/12/2024